Chemotherapy of acute lymphocytic leukemia of childhood

Holland, James F.; Glidewell, Oliver

doi:10.1002/1097-0142(197212)30:6<1480::aid-cncr2820300611>3.0.co;2-3

Cited by 102 publications

(20 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…' The lack of specificity of both chemotherapeutic agents and radiation therapy (RT) in terms of differentiating neoplastic cells from metabolically active normal cells might result in abnormalities of dental and facial development. [2][3][4][5][6] In addition to the direct effects of therapy on growing cells, an indirect effect might also occur due to altered hypothalmic-pituitary function resulting in diminished growth hormone produ~tion.~-" This in turn may also adversely effect odontogenesis and craniofacial development.…”

Section: S the Prognosis For Childhood Acute Lymphoblasticmentioning

confidence: 99%

Dentofacial development in long-term survivors of acute lymphoblastic leukemia: A comparison of three treatment modalities

Sonis

Tarbell²,

Valachovic

et al. 1990

Cancer

165

129

View full text Add to dashboard Cite

Ninety-seven children who were diagnosed with acute lymphoblastic leukemia before 10 years of age and treated with chemotherapy alone, chemotherapy plus 1800-cGy cranial irradiation (RT), or chemotherapy plus 2400-cGy RT were evaluated for effects of therapy on dentofacial development. All patients were seen at least 5 years postdiagnosis. Dental abnormalities were determined from panoramic radiographs, and craniofacial evaluations were made from lateral cephalometric radiographs. Ninety-one (94%) of all patients and 41 (100%) of patients younger than 5 years of age at diagnosis had abnormal dental development. The severity of these abnormalities was greater in children who received treatment before 5 years of age and in those who received RT. Observed dental abnormalities included tooth agenesis, arrested root development, microdontia, and enamel dysplasias. Craniofacial abnormalities occurred in 18 of 20 (90%) of those patients who received chemotherapy plus 2400-cGy RT before 5 years of age. Mean cephalometric values of this group showed significant deficient mandibular development. The results of this study suggest that the severity of dentofacial-developmental abnormalities secondary to antileukemia therapy are related to the age of the patient at the initiation of treatment and the use of cranial RT.

show abstract

Section: S the Prognosis For Childhood Acute Lymphoblasticmentioning

confidence: 99%

Dentofacial development in long-term survivors of acute lymphoblastic leukemia: A comparison of three treatment modalities

Sonis

Tarbell²,

Valachovic

et al. 1990

Cancer

165

129

View full text Add to dashboard Cite

show abstract

“…1,2 Clinical studies performed in the 1970s and 1980s showed that treatment intensification during maintenance improved the outcome of nonintensive protocols. 3,4 Among the combinations added to the thiopurine-methotrexate basic continuation therapy, reinductions of vincristine (VCR) and prednisone (PRED) have often been used and have improved treatment outcome for some patients. 5 A large retrospective analysis by the Childhood ALL Collaborative Group 6 suggested that for patients at standard or intermediate risk of relapse receiving a treatment regimen of moderate intensity, the addition of VCR ϩ PRED pulses to continuation therapy did improve the disease-free survival (DFS) from 59.5% to 68.9%.…”

Section: Introductionmentioning

confidence: 99%

Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951

Moerloose

Suciu

Bertrand

et al. 2010

Blood

View full text Add to dashboard Cite

“…In Slovakia, an ALL treatment protocol was initiated in the early 70s when Čáp, Koza and Černý worked out the fi rst protocol (0171), based on the work of American authors Holand et al, in which the treatment was already divided into stages of induction (prednisone, vincristine), consolidation (methotrexate, mercaptopurine), intensifi cation (prednisone, vincristine, methotrexate, mercaptoputine, cyclophosphamide), maintenance (prednisone, vincristine, methotrexate, mercaptopurine) and prophylaxis/treatment of leukaemia CNS (methotrexate and cytarabine intrathecal, cranial radiotherapy 24 Gy) [1,2]. Five years later, the 0276 protocol was created with the addition of L-asparaginase for induction and with the maintenance treatment extended from 72 to 132 weeks.…”

Section: Introductionmentioning

confidence: 99%

Results of acute lymphoblastic leukemia treatment in children in the Slovak Republic

Kaiserová

Bubanská

Oravkinova³

et al. 2011

memo

View full text Add to dashboard Cite

Treatment of childhood acute lymphoblastic leukemia (ALL) according to the 1st Slovak protocol started in the Slovak Republic in 1971 in eight pediatric departments. Gradually, two other protocols were written, and 496 children were treated with these three protocols from 1971 to 1992. Since 1992, all children have been treated in three pediatric oncological departments. From 1992 to 1996, protocols for standard and high-risk ALL were developed that were used for 111 children in Bratislava, while the centres in Banska Bystrica and Košice had started to use BFM protocols. Since 1997, all patients with ALL have been treated according to ALL BFM 95, and since 2002, they have been included in the ALL IC BFM 2002 study. We evaluated treatment results in the standard arm of ALL BFM 95 and compared it with previous Slovak protocols. Rates of complete remission increased from 90.6% in the fi rst Slovak protocol to 97.1% in BFM 95; EFS and OS increased from 0.46 and 0.50 to 0.67 and 0.72, respectively. Relapse rates decreased from 42% to 20.5%. EFS was signifi cantly worse in children with leukocyte counts >100 × 10 9 /l and in the HR group in comparison to standard-and medium-risk groups. OS was also signifi cantly worse in T-cell ALL than in B-cell ALL. Death rates in the 1st complete remission decreased gradually in the Slovak protocols from 10.4% to 1.8%, but were high in BFM 95 (10.8%) due to more intensive therapy and initial unsatisfactory experiences with BFM protocols. All parameters improved in the ALL IC BFM 2002 study.

show abstract

Chemotherapy of acute lymphocytic leukemia of childhood

Cited by 102 publications

References 9 publications

Dentofacial development in long-term survivors of acute lymphoblastic leukemia: A comparison of three treatment modalities

Dentofacial development in long-term survivors of acute lymphoblastic leukemia: A comparison of three treatment modalities

Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951

Results of acute lymphoblastic leukemia treatment in children in the Slovak Republic

Contact Info

Product

Resources

About